Entera Bio Ltd

Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613

Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds

Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates

Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis

Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board